Revenue expanding 27% year-over-year places the company at the top of its industry peer group on growth, and a volume surge of 2.8 times the average on an up-move alongside rising on-balance volume signals institutional accumulation — yet business quality sits just below the minimum acceptable threshold, and the share price trades within 1% of the analyst-derived price target, leaving near-zero reward against meaningful downside.
Thesis pillars
- Industry Leading Revenue Growth→Stable
- Technical Accumulation Uptrend↓Deteriorating
- Quality Below Minimum Floor↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
AxoGen, Inc. (AXGN) Stock Analysis
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $35.14, but acceptable to hold if already in. Reasons: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2); Negative momentum.
AxoGen develops and commercializes peripheral nerve repair products including Avance Nerve Graft, Axoguard Nerve Connector and Protector, and Avive+ Soft Tissue Matrix, sold primarily in the U.S. Approximately 60% of revenues derive from the Avance product family, with... Read more
Hold if already holding. Not a fresh buy at $35.14, but acceptable to hold if already in. Reasons: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2); Negative momentum. Chart setup: No clear chart pattern; technical signals are mixed. Mixed signals. Hold existing position. Score 5.7/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
About AxoGen, Inc.
About AxoGen, Inc.
AxoGen received FDA biologics license approval for Avance on December 3, 2025 — the first BLA-approved acellular nerve scaffold for peripheral nerve repair — with commercial availability expected in early Q2 2026. The company's seven-product portfolio addresses a total addressable market estimated at $5.6 billion; approximately 60% of revenues come from Avance Products, with the remainder from Axoguard and Avive+ lines sold in the U.S., Canada, Germany, the United Kingdom, Spain and several other countries.
AxoGen earns revenue through direct sales to hospitals and ambulatory surgery centers, with reimbursement driven by Category I CPT codes 64912 and +64913, established in January 2018. Effective January 1, 2026, CMS created a new Ambulatory Payment Category 5433 for level 3 nerve repair, improving reimbursement for Avance Nerve Graft procedures by 96% in hospital outpatient centers and 221% in ambulatory surgery centers versus 2019 levels. The Axoguard Nerve Connector and Nerve Protector are distributed exclusively through an agreement with Evergen through December 31, 2030; Evergen also manufactures Axoguard HA+ Nerve Protector and Axoguard Nerve Cap. Avance is processed at the company's APC Facility in Vandalia, Ohio, with terminal sterilization performed by a single third-party contractor. The TAM spans extremities ($2.9 billion), oral maxillofacial ($1.2 billion), breast ($677 million) and urology ($754 million).
Show full overview
Portions of the FDA's December 3, 2025 BLA approval were granted under the accelerated approval pathway: continued authorization for sensory nerve discontinuities greater than 25mm and for mixed and motor nerve discontinuities is contingent on a post-marketing confirmatory study. The FDA requires a final protocol by February 5, 2026, study completion by December 5, 2030, and a final report by June 5, 2031, with progress reports every 180 days starting May 31, 2026. If AxoGen fails to complete the study on schedule or to verify clinical benefit, the FDA may withdraw those indications on an expedited basis — a binary outcome for the product line accounting for approximately 60% of total revenue.
See also: Healthcare · Medical Devices
From AxoGen, Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-10-15Recent Developments — AxoGen, Inc.
Latest news
- NEWS Axogen Inc (AXGN) Stock Up 3.3% but GF Value Says Overvalued -- GF Score: 64/100 - GuruFocus — GuruFocus positive
- NEWS Truist initiates AxoGen stock with buy rating on growth potential - Investing.com — Investing.com positive
- NEWS AxoGen (AXGN) Projected to Release Quarterly Earnings on Wednesday - MarketBeat — MarketBeat neutral
- NEWS Jefferies Remains a Buy on AxoGen (AXGN) - The Globe and Mail — The Globe and Mail neutral
- NEWS Axogen, Inc. agreed to acquire BioCircuit Technologies, Inc. for approximately $200 million. - marketscreener.com — marketscreener.com positive
Generated 2026-10-15T11:37:20Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $35.14, but acceptable to hold if already in. Reasons: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2); Negative momentum. Chart setup: No clear chart pattern; technical signals are mixed. Mixed signals. Hold existing position. Target $46.69 (+32.9%), stop $33.98 (−3.4%), A.R:R 3.5:1. Score 5.7/10, moderate confidence.
Take-profit target: $46.69 (+32.9% upside). Target $46.69 (+32.9%), stop $33.98 (−3.4%), A.R:R 3.5:1. Stop-loss: $33.98.
V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2); Negative momentum; Value-trap signals (2/5): Margin compression (op margin -3.1%), Material insider selling (4 sells, 0.22% of cap).
AxoGen, Inc. trades at a P/E of N/A (forward 50.2). TrendMatrix value score: 6.1/10. Verdict: Hold.
16 analysts cover AXGN with a consensus score of 4.2/5. Average price target: $54.
What does AxoGen, Inc. do?AxoGen develops and commercializes peripheral nerve repair products including Avance Nerve Graft, Axoguard Nerve...
AxoGen develops and commercializes peripheral nerve repair products including Avance Nerve Graft, Axoguard Nerve Connector and Protector, and Avive+ Soft Tissue Matrix, sold primarily in the U.S. Approximately 60% of revenues derive from the Avance product family, with reimbursement supported by Category I CPT codes established in 2018. The Axoguard line is sourced exclusively through a distribution and manufacturing agreement with Evergen expiring December 31, 2030.